2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Enrolling by invitation
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Fasting
9
Prostatic Neoplasms
3
Breast Neoplasms
3
Intermittent Fasting
2
Colorectal Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
1
Solitary Fibrous Tumors
1
Sarcoma
1
Polycystic Ovary Syndrome
1
Ovarian Neoplasms
1
Neoplasms
1
Lymphoma
1
Liposarcoma
1
Infertility
1
Histiocytoma, Malignant Fibrous
1
Glioma
1
Fibrosis
1
Fasting in Malignant Solid Tumors
1
Esophageal Neoplasms
1
Dermatofibrosarcoma
1
Childhood Cancer Survivors
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Cyclophosphamide
447
Rituximab
406
Etoposide
225
Vincristine
217
Doxorubicin
204
Filgrastim
201
Prednisone
178
Cytarabine
160
Radiotherapy
152
fludarabine phosphate
148
Methotrexate
137
Peripheral Blood Stem Cell Transplantation
130
Melphalan
128
fludarabine
116
Busulfan
101
Dexamethasone
93
Tacrolimus
76
Carmustine
74
Granulocyte Colony-Stimulating Factor
73
Mycophenolic Acid
72
Gemcitabine
66
Bortezomib
65
Antilymphocyte Serum
65
Whole-Body Irradiation
63
Bendamustine Hydrochloride
63
Lenalidomide
62
Cyclosporine
62
Ifosfamide
58
sargramostim
51
Methylprednisolone
49
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma
×
Angptl4 protein, mouse
×
Clear all
NCT06645093
2026-03-10
FasteStudien
University of Oslo
Phase NA
Enrolling by invitation
40 enrolled